RESUMEN
Most genotoxic anticancer agents fail in tumors with intact DNA repair. Therefore, trabectedin, anagent more toxic to cells with active DNA repair, specifically transcription-coupled nucleotide excision repair (TC-NER), provides therapeutic opportunities. To unlock the potential of trabectedin and inform its application in precision oncology, an understanding of the mechanism of the drug's TC-NER-dependent toxicity is needed. Here, we determine that abortive TC-NER of trabectedin-DNA adducts forms persistent single-strand breaks (SSBs) as the adducts block the second of the two sequential NER incisions. We map the 3'-hydroxyl groups of SSBs originating from the first NER incision at trabectedin lesions, recording TC-NER on a genome-wide scale. Trabectedin-induced SSBs primarily occur in transcribed strands of active genes and peak near transcription start sites. Frequent SSBs are also found outside gene bodies, connecting TC-NER to divergent transcription from promoters. This work advances the use of trabectedin for precision oncology and for studying TC-NER and transcription.
Asunto(s)
Reparación por Escisión , Neoplasias , Humanos , Trabectedina , Transcripción Genética , Medicina de Precisión , Reparación del ADN , Daño del ADN , ADN/genética , Nucleótidos , Roturas del ADNRESUMEN
Fungal glucosylceramide (GlcCer) is a plasma membrane sphingolipid in which the sphingosine backbone is unsaturated in carbon position 8 (C8) and methylated in carbon position 9 (C9). Studies in the fungal pathogen, Cryptococcus neoformans, have shown that loss of GlcCer synthase activity results in complete loss of virulence in the mouse model. However, whether the loss of virulence is due to the lack of the enzyme or to the loss of the sphingolipid is not known. In this study, we used genetic engineering to alter the chemical structure of fungal GlcCer and studied its effect on fungal growth and pathogenicity. Here we show that unsaturation in C8 and methylation in C9 is required for virulence in the mouse model without affecting fungal growth in vitro or common virulence factors. However, changes in GlcCer structure led to a dramatic susceptibility to membrane stressors resulting in increased cell membrane permeability and rendering the fungal mutant unable to grow within host macrophages. Biophysical studies using synthetic vesicles containing GlcCer revealed that the saturated and unmethylated sphingolipid formed vesicles with higher lipid order that were more likely to phase separate into ordered domains. Taken together, these studies show for the first time that a specific structure of GlcCer is a major regulator of membrane permeability required for fungal pathogenicity.
Asunto(s)
Fenómenos Biofísicos/fisiología , Membrana Celular/fisiología , Cryptococcus neoformans/patogenicidad , Cryptococcus neoformans/ultraestructura , Glucosilceramidas/química , Virulencia , Animales , Membrana Celular/química , Criptococosis/mortalidad , Criptococosis/patología , Cryptococcus neoformans/química , Cryptococcus neoformans/genética , Femenino , Glucosilceramidas/genética , Ratones , Ratones Endogámicos CBA , Organismos Modificados Genéticamente , Virulencia/genéticaRESUMEN
Cryptococcus neoformans is an opportunistic fungal pathogen and the causative agent of the disease cryptococcosis. Cryptococcosis is initiated as a pulmonary infection and in conditions of immune deficiency disseminates to the blood stream and central nervous system, resulting in life-threatening meningoencephalitis. A number of studies have focused on the development of a vaccine against Cryptococcus, primarily utilizing protein-conjugated components of the Cryptococcus polysaccharide capsule as antigen. However, there is currently no vaccine against Cryptococcus in the clinic. Previous studies have shown that the glycosphingolipid, glucosylceramide (GlcCer), is a virulence factor in C. neoformans and antibodies against this lipid inhibit fungal growth and cell division. In the present study, we have investigated the possibility of using GlcCer as a therapeutic agent against C. neoformans infections in mouse models of cryptococcosis. GlcCer purified from a non-pathogenic fungus, Candida utilis, was administered intraperitoneally, prior to infecting mice with a lethal dose of C. neoformans. GlcCer administration prevented the dissemination of C. neoformans from the lungs to the brain and led to 60% mouse survival. GlcCer administration did not cause hepatic injury and elicited an anti-GlcCer antibody response, which was observed independent of the route of administration and the strains of mouse. Taken together, our results suggest that fungal GlcCer can protect mice against lethal doses of C. neoformans infection and can provide a viable vaccination strategy against Cryptococcus.
Asunto(s)
Criptococosis/prevención & control , Vacunas Fúngicas/administración & dosificación , Glucosilceramidas/administración & dosificación , Animales , Anticuerpos/química , Cryptococcus neoformans , Citocinas/metabolismo , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Femenino , Recuento de Leucocitos , Hígado/microbiología , Pruebas de Función Hepática , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos CBA , Vacunación , Factores de Virulencia/químicaRESUMEN
Cryptococcosis caused by Cryptococcus neoformans and Cryptococcus gattii affects a large population and is a cause of significant morbidity and mortality. Despite its public health burden, there are currently no vaccines against cryptococcosis and new strategies against such infections are needed. In this study, we demonstrate that C. neoformans has the biochemical ability to metabolize sterylglucosides (SGs), a class of immunomodulatory glycolipids. Genetic manipulations that eliminate cryptococccal sterylglucosidase lead to the accumulation of SGs and generate a mutant strain (Δsgl1) that is non-pathogenic in the mouse models of cryptococcosis. Interestingly, this mutant strain acts as a vaccine strain and protects mice against cryptococcosis following infection with C. neoformans or C. gattii. The immunity induced by the Δsgl1 strain is not CD4(+) T-cells dependent. Immunocompromised mice, which lack CD4(+) T-cells, are able to control the infection by Δsgl1 and acquire immunity against the challenge by wild-type C. neoformans following vaccination with the Δsgl1 strain. These findings are particularly important in the context of HIV/AIDS immune deficiency and suggest that the Δsgl1 strain might provide a potential vaccination strategy against cryptococcosis.
RESUMEN
UNLABELLED: Recent estimates suggest that >300 million people are afflicted by serious fungal infections worldwide. Current antifungal drugs are static and toxic and/or have a narrow spectrum of activity. Thus, there is an urgent need for the development of new antifungal drugs. The fungal sphingolipid glucosylceramide (GlcCer) is critical in promoting virulence of a variety of human-pathogenic fungi. In this study, we screened a synthetic drug library for compounds that target the synthesis of fungal, but not mammalian, GlcCer and found two compounds [N'-(3-bromo-4-hydroxybenzylidene)-2-methylbenzohydrazide (BHBM) and its derivative, 3-bromo-N'-(3-bromo-4-hydroxybenzylidene) benzohydrazide (D0)] that were highly effective in vitro and in vivo against several pathogenic fungi. BHBM and D0 were well tolerated in animals and are highly synergistic or additive to current antifungals. BHBM and D0 significantly affected fungal cell morphology and resulted in the accumulation of intracellular vesicles. Deep-sequencing analysis of drug-resistant mutants revealed that four protein products, encoded by genes APL5, COS111, MKK1, and STE2, which are involved in vesicular transport and cell cycle progression, are targeted by BHBM. IMPORTANCE: Fungal infections are a significant cause of morbidity and mortality worldwide. Current antifungal drugs suffer from various drawbacks, including toxicity, drug resistance, and narrow spectrum of activity. In this study, we have demonstrated that pharmaceutical inhibition of fungal glucosylceramide presents a new opportunity to treat cryptococcosis and various other fungal infections. In addition to being effective against pathogenic fungi, the compounds discovered in this study were well tolerated by animals and additive to current antifungals. These findings suggest that these drugs might pave the way for the development of a new class of antifungals.
Asunto(s)
Antifúngicos/aislamiento & purificación , Antifúngicos/farmacología , Compuestos de Bencilo/aislamiento & purificación , Compuestos de Bencilo/farmacología , Vías Biosintéticas/efectos de los fármacos , Hongos/efectos de los fármacos , Esfingolípidos/biosíntesis , Animales , Antifúngicos/efectos adversos , Antifúngicos/toxicidad , Compuestos de Bencilo/efectos adversos , Compuestos de Bencilo/toxicidad , Candidiasis/tratamiento farmacológico , Línea Celular , Supervivencia Celular/efectos de los fármacos , Recuento de Colonia Microbiana , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Sinergismo Farmacológico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Hongos/citología , Hongos/metabolismo , Hongos/fisiología , Macrófagos/efectos de los fármacos , Macrófagos/fisiología , Ratones , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Microscopía Electrónica de Transmisión , Estructura Molecular , Esfingolípidos/antagonistas & inhibidores , Resultado del TratamientoRESUMEN
Cryptococcosis is a life-threatening infection caused by pathogenic fungi of the genus Cryptococcus. Infection occurs upon inhalation of spores, which are able to replicate in the deep lung. Phagocytosis of Cryptococcus by macrophages is one of the ways that the disease is able to spread into the central nervous system to cause lethal meningoencephalitis. Therefore, study of the association between Cryptococcus and macrophages is important to understanding the progression of the infection. The present study describes a step-by-step protocol to study macrophage infectivity by C. neoformansin vitro. Using this protocol, the role of host sterols on host-pathogen interactions is studied. Different concentrations of methyl--cyclodextrin (MCD) were used to deplete cholesterol from murine reticulum sarcoma macrophage-like cell line J774A.1. Cholesterol depletion was confirmed and quantified using both a commercially available cholesterol quantification kit and thin layer chromatography. Cholesterol depleted cells were activated using Lipopolysacharide (LPS) and Interferon gamma (IFNγ) and infected with antibody-opsonized Cryptococcus neoformans wild-type H99 cells at an effector-to-target ratio of 1:1. Infected cells were monitored after 2 hr of incubation with C. neoformans and their phagocytic index was calculated. Cholesterol depletion resulted in a significant reduction in the phagocytic index. The presented protocols offer a convenient method to mimic the initiation of the infection process in a laboratory environment and study the role of host lipid composition on infectivity.
Asunto(s)
Colesterol/deficiencia , Cryptococcus neoformans/inmunología , Macrófagos/metabolismo , Macrófagos/microbiología , Fagocitosis/inmunología , Animales , Línea Celular , Colesterol/inmunología , Colesterol/metabolismo , Criptococosis/inmunología , Criptococosis/metabolismo , Criptococosis/microbiología , Interacciones Huésped-Patógeno , Interferón gamma/inmunología , Pulmón/inmunología , Macrófagos/inmunología , Ratones , Polisacáridos/inmunologíaRESUMEN
Cryptococcus neoformans is a facultative intracellular pathogen, which can replicate in the acidic environment inside phagolysosomes. Deletion of the enzyme inositol-phosphosphingolipid-phospholipase-C (Isc1) makes C. neoformans hypersensitive to acidic pH likely by inhibiting the function of the proton pump, plasma membrane ATPase (Pma1). In this work, we examined the role of Isc1 on Pma1 transport and oligomerization. Our studies showed that Isc1 deletion did not affect Pma1 synthesis or transport, but significantly inhibited Pma1 oligomerization. Interestingly, Pma1 oligomerization could be restored by supplementing the medium with phytoceramide. These results offer insight into the mechanism of intracellular survival of C. neoformans.
Asunto(s)
Adenosina Trifosfatasas/química , Adenosina Trifosfatasas/metabolismo , Membrana Celular/enzimología , Cryptococcus neoformans/enzimología , Fosfolipasas de Tipo C/metabolismo , Adenosina Trifosfatasas/biosíntesis , Membrana Celular/efectos de los fármacos , Ceramidas/farmacología , Cryptococcus neoformans/citología , Cryptococcus neoformans/genética , Cryptococcus neoformans/fisiología , Estabilidad de Enzimas , Eliminación de Gen , Espacio Intracelular/microbiología , Multimerización de Proteína/efectos de los fármacos , Estructura Cuaternaria de Proteína , Transporte de Proteínas/efectos de los fármacos , Fosfolipasas de Tipo C/deficiencia , Fosfolipasas de Tipo C/genéticaRESUMEN
The fungal pathogen Cryptococcus neoformans (Cn) is a serious threat to immunocompromised individuals, especially for HIV patients who develop meningoencephalitis. For effective cryptococcal treatment, novel antifungal drugs or innovative combination therapies are needed. Recently, sphingolipids have emerged as important bioactive molecules in the regulation of microbial pathogenesis. Previously we reported that the sphingolipid pathway gene, ISC1, which is responsible for ceramide production, is a major virulence factor in Cn infection. Here we report our studies of the role of ISC1 during genotoxic stress induced by the antineoplastic hydroxyurea (HU) and methyl methanesulfonate (MMS), which affect DNA replication and genome integrity. We observed that Cn cells lacking ISC1 are highly sensitive to HU and MMS in a rich culture medium. HU affected cell division of Cn cells lacking the ISC1 gene, resulting in cell clusters. Cn ISC1, when expressed in a Saccharomyces cerevisiae (Sc) strain lacking its own ISC1 gene, restored HU resistance. In macrophage-like cells, although HU affected the proliferation of wild type (WT) Cn cells by 50% at the concentration tested, HU completely inhibited Cn isc1Δ cell proliferation. Interestingly, our preliminary data show that mice infected with WT or Cn isc1Δ cells and subsequently treated with HU had longer lifespans than untreated, infected control mice. Our work suggests that the sphingolipid pathway gene, ISC1, is a likely target for combination therapy with traditional drugs such as HU.
RESUMEN
Glycosaminoglycans like heparin and heparin sulfate in follicular fluid induce changes in the intracellular environment during the spermatozoal functional maturation. We previously reported the isolation, purification and partial characterization of a heparin binding sperm membrane protein (HBSM). In the present study, the amino acids analysis provided evidence of a single sequence, which suggest the homogeneity of the purified HBSM. Fourteen amino acids--(1)A D T I V A V E L D T Y P N(14)--correspond to the amino terminal sequence of Concanavalin A (Con A) and contain 45.2% carbohydrate by weight. HBSM possess mitogenic property on lymphocytes with comparable magnitude to the well-known mitogen; Con A, inducing 83% radiolabel thymidine incorporation in growing lymphocytes. Unlike Con A, there was no agglutination of cell by HBSM upto 5 ng/ml concentration. Interestingly, we found that heparin and chondroitin sulfate-conjugated HBSM inhibit the proliferative activity. Similar effect was also found with an in-house isolate sulfated glycans; G-I (28% sulfate). In contrast, there was no inhibition by the desulfated form; G-ID. Altogether, our data suggest that the mechanism of cell proliferative pathway may be different for HBSM and Con A.
Asunto(s)
Membrana Celular/metabolismo , Eritrocitos/citología , Eritrocitos/fisiología , Heparina/metabolismo , Mitógenos/metabolismo , Mitógenos/farmacología , Espermatozoides/metabolismo , Aglutinación/efectos de los fármacos , Secuencia de Aminoácidos , Animales , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Eritrocitos/efectos de los fármacos , Cabras , Masculino , Mitógenos/química , Datos de Secuencia Molecular , Ratas , Ratas Sprague-Dawley , Homología de Secuencia de Aminoácido , OvinosRESUMEN
Protein tyrosine phosphorylation in spermatozoa is associated with epididymal maturation and though to be central for attainment of a capacitated state and expression of hyperactivated motility. Heparin, the most highly sulfated glycosaminoglycans, was also the most potent at stimulating the acrosomal reaction in bovine epididymal spermatozoa. Studies using radiolabeled inorganic phosphate showed 11-fold increase (32)Pi incorporation in heparin-binding sperm membrane protein (HBSM) during spermatozoal capacitation, and the phosphorylation occurs at the tyrosine residue. Epididymal spermatozoa were induced to undergo capacitation and acrosome reaction by 70% when the cells were incubated in BWW medium supplemented with heparin. The spermatozoa pre-treated with anti-HBSM antibody showed 46% reduction in the hyperactivated motility and lowers the acrosome reaction. This was confirms by measuring the hydrolysis of benzoyl-l-arginine ethyl ether (BAEE) by the acrosomal enzyme; acrosin. The preliminary finding suggests that HBSM may play an important role in the sperm capacitation and acrosome reaction.
Asunto(s)
Reacción Acrosómica/fisiología , Acrosoma/fisiología , Heparina/administración & dosificación , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Capacitación Espermática/fisiología , Espermatozoides/fisiología , Acrosoma/efectos de los fármacos , Reacción Acrosómica/efectos de los fármacos , Animales , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Células Cultivadas , Relación Dosis-Respuesta a Droga , Cabras , Masculino , Proteínas de la Membrana/metabolismo , Fosforilación , Capacitación Espermática/efectos de los fármacos , Espermatozoides/efectos de los fármacosRESUMEN
OBJECTIVE: To characterize the major membrane protein of goat spermatozoa. DESIGN: Basic research. SETTING: Samples collected from local slaughterhouse and study conducted in an academic research environment. PATIENT(S): Goat epididymal tissue. INTERVENTION(S): Goat epididymal tissues were collected immediately after slaughter and the spermatozoa were isolated within 2 hours. Sperm immobilization test was performed with motile spermatozoa at 32 degrees C within 3-4 hours of collection and isolation of the cells. MAIN OUTCOME MEASURE(S): The heparin-binding sperm membrane protein (HBSM) of goat is insensitive to trypsin and its antisera immobilize spermatozoa in presence of complement. RESULT(S): Forty-two percent of membrane protein could be extracted with 0.25% (wt/vol) 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS) from the isolated sperm membrane. By heparin-affinity chromatography, 46% of the extracted protein was recovered. Positive hybridization with radiolabeled heparin on western transfer confirmed the heparin-binding property of the protein (HBSM). Heparin binding to HBSM is an ionic bondage and can be disrupted by 1 M NaCl, as revealed by 86% recovery of the radiolabeled heparin in trichloroacetic acid-precipitated supernatant of [(125)I] heparin-HBSM conjugate. Heparin-binding sperm membrane protein is localized at the anterior region of the spermatozoal head. No detectable proteolytic fragment of HBSM was detected after limited digestion by trypsin. Heparin-binding sperm membrane protein antisera (1:10,000 titer) developed from rabbit did not recognize the denatured protein. The antisera inhibited spermatozoal motility in a complement-dependent manner. CONCLUSION(S): We suggest that the heparin-binding motif of the spermatozoal membrane protein might be required in modulation of the spermatozoal motility.